JN
John Newman Canaccord Genuity Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
18
Avg Return
Past Year
Past Year
3.1%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
88.9%
Neutral
11.1%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Technology
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
Medical Devices
Technology
Software - Infrastructure
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Buy
Maintained
| $22 |
291%
upside
| 2 | -26% |
0
%
| 13 Mar ‘26 3 months ago |
|
|
|
Buy
Maintained
| $25 |
192%
upside
| 1 | -3% |
0
%
| 13 Mar ‘26 3 months ago |
|
|
|
Buy
Maintained
| $14 |
622%
upside
| 1 | -0.4% |
0
%
| 13 Mar ‘26 3 months ago |
|
|
|
Buy
Maintained
| $171 |
88%
upside
| 1 | +9.1% |
0
%
| 11 Mar ‘26 3 months ago |
|
|
|
Hold
Downgraded
| $6 |
40%
downside
| 2 | -66% |
0
%
| 13 Jan ‘26 5 months ago |
|
|
|
Buy
Maintained
| $18 |
122%
upside
| 1 | -11% |
0
%
| 6 Jan ‘26 5 months ago |
|
|
|
Buy
Maintained
| $130 |
13%
upside
| 2 | +21% |
0
%
| 8 Dec ‘25 6 months ago |
|
|
|
Buy
Maintained
| $1,057 |
72%
upside
| 5 | +6.5% |
0
%
| 4 Dec ‘25 6 months ago |
|
|
|
Buy
Initiated
| $10 |
390%
upside
| 1 | +4.6% |
0
%
| 3 Dec ‘25 6 months ago |
|
|
|
Buy
Initiated
| $126 |
2%
upside
| 1 | +4% |
0
%
| 12 Nov ‘25 7 months ago |
|
|
|
Buy
Maintained
| $21 |
78%
upside
| 1 | -13% |
0
%
| 21 Oct ‘25 7 months ago |
|
|
|
Hold
Downgraded
| $97 |
8%
upside
| 1 | – |
–
| 30 Sep ‘25 8 months ago |
|